Enzene Biosciences, part of Indian pharmaceutical company Alkem Laboratories, has unveiled its new $50m biomanufacturing facility in Hopewell, New Jersey, US.
Initially announced in June 2023, Enzene’s new site spans over 7,430sqm and is its first major manufacturing investment in the country. It will also generate 50 jobs for the local economy, with the number eventually expected to reach 300.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The site will focus on fed-batch drug substance manufacturing and utilise the ‘EnzeneX 2.0’ platform. It is an advanced continuous manufacturing technology which will enhance sustainability, scalability, and efficiency. Additionally, it will achieve ten times the yield of traditional methods while also lowering costs to $40 per gram.
Governor of New Jersey, Phil Murphy, applauded Enzene’s decision to locate its manufacturing facility in the region.
“Their decision reflects our state’s strength as a hub for global business and innovation, and the deep cultural ties that bind New Jersey and India,” he added.
Himanshu Gadgil, CEO of Enzene, stated that the facility will provide a cost-efficient, high-yield, biomanufacturing solution.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“It will complement our facilities in India to provide global supply solutions,” he added.
Headquartered in the Indian city of Pune, Enzene Biosciences is a contract development and manufacturing organisation. It has over 600 employees presently.
